TCM Ltd is a diversified company that primarily trades medical diagnostic equipment and reagents, installs solar power plants, and manufactures cattle feed, while also managing a legacy real estate portfolio for development.
The company lacks a durable competitive advantage, as evidenced by its negative average ROCE and net margins. Its shift from chemical manufacturing to unrelated fields like medical diagnostics and solar installation suggests a lack of specialized expertise or scale in any single high-barrier market.
Capital allocation has been poor, characterized by the abandonment of its core chemical business and a pivot into low-margin trading and solar projects that have failed to generate positive returns on equity. Significant funds were recently used to settle long-standing liabilities with Godrej Properties to free up land for joint development.
Five years out, the company's pivot into solar and cattle feed proved to be a value-destroying distraction, as these low-margin commodity trades failed to cover the interest on director-funded debt. The land development deal with Godrej, once the primary hope for a liquidity event, became mired in litigation or stalled, leaving the company with non-productive assets and no operating cash flow. As the core chemical business remained shuttered, the constant shifting between unrelated industries exhausted the remaining capital, leading to a slow-motion liquidation where shareholders were diluted to zero to satisfy statutory dues and unsecured lenders.
RichFakir rates TCM Ltd's business quality as poor — 12/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
RichFakir's educational verdict on TCM Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
View the full live analysis →